Quintessence Biosciences, Inc.

Promega Corporation

Wisconsin Alumni Research Foundation

Ophidian Pharmaceuticals, Inc.

Other

Ochidian Pharmaceuticals, Inc.

John A Kink

Laura Strong

James Arthur Williams

Douglas C Stafford

Tony Klink

William E Fahl

Katherine L Worledge

Sean B Carroll

Peiman Hematti

Christopher M Clemens

Nalini Raghavachari

Ming Zhu

Mark N Shahan

Bruce S Thalley

Ronald Thaddeus Raines

Vladimir S Trubetskoy

Ray Vanderby

Thomas J Rutkoski

Eric G Schmuck

Joseph R Firca

Amish Naresh Raval

Terence E Ryan

Connie Sue Chamberlain

Nisha V Padhye

John A Todd

Christian M Capitini

Badr Saeed

Anna Elizabeth Breiner Clements

Amish N Raval

Laura E Strong

The invention relates to an ex vivo generated population of tissue-specific anti-inflammatory macrophages and methods of making and using such macrophages.

Generation of therapeutic cells using extracellular components of target organs

An ex vivo generated population of tissue-specific alternatively-activated macrophages and methods of making and using such macrophages for treating orthopedic injury are provided.

Macrophage cell therapy to treat orthopedic injury

The disclosure relates to an ex vivo generated population of educated macrophages specific to LPS and methods of making and using such macrophages.

LPS priming of stromal cells to generate LPS-specific exosome educated macrophages

Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.

Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy

The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.

Therapeutic ribonucleases

The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.

Methods and compositions for the treatment of cancer

The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).

Modified ribonucleases

Compositions and methods for ribonuclease-based therapeutics

Growing community of inventors

Madison, WI, United States of America

John A Kink